Adma Biologics ADMA
NASDAQ ADMA
$11.31 +0.24 (+2.21%)
As of: Oct 20, 2026 · 2:21 PM EDT

Adma Biologics (ADMA) Notes Payables (2011 - 2017)

Updated

Adma Biologics (ADMA) recorded Notes Payables of $6.67 million in Q2 2017, unchanged from the prior quarter.

Analysis

Adma Biologics (ADMA) Notes Payables (2011 - 2017) Analysis & Trends

At the end of FY2016, Adma Biologics reported Notes Payables of $6.11 million.

  • Annual Notes Payables has a five-year compound annual growth rate of 68.5% (FY2011 to FY2016).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,149.92 Bn 1,118.50 Bn 19.71 Bn
2 Johnson & Johnson 624.76 Bn 543.28 Bn 17.26 Bn
3 AbbVie 512.33 Bn 485.44 Bn 12.70 Bn
4 Merck 366.04 Bn 320.42 Bn 12.21 Bn
5 Novartis Ag 297.83 Bn 261.82 Bn 11.24 Bn
6 Astrazeneca 261.44 Bn 235.12 Bn 12.86 Bn
7 Amgen 234.73 Bn 190.13 Bn 7.24 Bn
8 Gilead Sciences 194.34 Bn 168.53 Bn 6.22 Bn
9 Pfizer 172.37 Bn 119.01 Bn 10.94 Bn
10 Adma Biologics 2.58 Bn 2.16 Bn 86.28 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 6.67 Mn
Mar 31, 2017 6.67 Mn
Dec 31, 2016 6.11 Mn
Dec 31, 2011 450,000.00
API Access

Adma Biologics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=ADMA&period=max&api_key=YOUR_API_KEY